Intracavernosal self-injection therapy in men with erectile dysfunction: Satisfaction and attrition in 119 patients

International Journal of Impotence Research

Volumn 11, Issue 3, 1999, Pages 145-151

  Rowland, D L ^a,b   Boedhoe, H S M ^b   Dohle, G ^b   Slob, A K ^b  

^a VALPARAISO UNIVERSITY   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Attrition; Compliance; Erectile dysfunction; ICI; Impotence; Premature ejaculation; Satisfaction; Self injection therapy

Indexed keywords

PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1; VASOACTIVE AGENT;

ADULT; ARTICLE; DRUG EFFICACY; ERECTILE DYSFUNCTION; FOLLOW UP; HUMAN; INTRACAVERNOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PENIS ERECTION; PREMATURE EJACULATION; PRIORITY JOURNAL; SELF CARE; SIDE EFFECT;

EID: 0032999275     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900397     Document Type: Article

References (28)

1. Zentgrapf M, Ludwig G, Ziegler M. How safe is the treatment of impotence with intracavernous autoinjection. Eur Urol 1989; 16: 165-171.
2. Waldhauser M, Schramek P. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol 1988; 140: 525-527.
3. Lee LM, Stevenson RWD, Szasz G. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison. J Urol 1989; 141: 549-550.
4. Ishii N, Watanabe H, Irisawa C, Kikuchi Y. Therapeutic trial with prostaglandin E1 for organic impotence. In: Abstract Book 2nd World Meeting on Impotence. Prague, Czech, 1986.
5. Stackl W, Hasun R, Marberger M. Intracavernous injection of prostaglandin E1 in impotent men. J Urol 1988; 140: 66-68.
6. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 155: 802-815.
7. Godschalk M et al. Long-term efficacy of a new formulation of prostaglandin E1as treatment for erectile failure. J Urol 1996; 155: 915-917.
8. Althof SE et al. Sexual, psychological, and marital impact of self-injection of papaverine and phentolamine: a long term prospective study. J Sex Marital Ther 1991; 17: 101-111.
9. Gall H et al. Long-term results of corpus cavernosum autoinjection therapy for chronic erectile dysfunction. Andrologia 1992; 24: 285-292.
10. Alhtof SE et al. Why do so many people drop out from auto-injection therapy for impotence? J Sex Marital Ther 1991; 15: 122-129.
11. Sundaram CP et al. Long term follow-up of patients receiving injection therapy for erectile dysfunction. Urology 1997; 49: 932-935.
12. Irwin MB, Kata EJ. High attrition rate with intracavernous injection of prostaglandin E1 for impotency. Urology 1994; 43: 84-87.
13. Weiss JN, Badlani GH, Curn RR, Gurn NB. Reasons for dropout rate with self-injection therapy for impotence, Int J Impot Res 1994; 6: 121-124.
14. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. New Engl J Med 1998; 338: 1397-1404.
15. Witjes WPJ et al. The efficacy and acceptance of intracavernous autoinjection therapy with the combination of papaverine/phentolamine: A prospective multicentre trial in 60 patients. Int J Impot Res 1992; 4: 65-72.
16. Rowland DL, Cooper SE, Slob AK. Genital and psychoaffective response to erotic stimulation in sexually functional and dysfunctional men. J Abnorm Psych 1998; 105: 194-203.
17. Haensel SM, Rowland DL, Kallan K, Slob AK. Clomipramine and sexual function in men with premature ejaculation and controls. J Urol 1996; 156: 1310-1315.
18. Incrocci L, Hop WCJ, Slob AK. Visual erotic and vibrotactile stimulation and intracavernous injection in screening men with erectile dysfunction: a 3 yr experience with 406 cases. Int J Impot Res 1996; 8: 227-232.
19. Slob AK, Blom JHM, van der Werff ten Bosch JJ. Erection problems in medical practice: Differential diagnosis with relatively simple method. J Urol 1990; 146: 46-50.
20. Speckens AEM et al. A prospective long-term follow up study of patients evaluated for erectile dysfunction: outcome and associated factors. Int J Impot Res 1995; 7: 101-110.
21. Lottman PEM, Hendriks JCM, Vruggink PA, Meuleman EJH. The impact of marital satisfaction and psychological counselling on the outcome of ICI-treatment in men with ED. Int J Impot Res 1998; 10: 83-87.
22. Flynn RJ, Williams G. Long-term follow-up of patients with erectile dysfunction commenced on self-injection with intracavernosal papaverine with or without phentolamine. Br J Urol 1996; 78: 628-631.
23. Armstrong DKB, Convery AG, Dinsmore WW. Reasons for patient drop-out from an intercavernous auto-injection programme for erectile dysfunction. Br J Urol 1994; 74: 99-101.
24. Casabé A et al. Drop-out reasons and complication? in self-injection therapy with a triple vasoactive drug mixture in sexual erectile dysfunction. Int J Impot Res 1998; 10: 5-9.
25. Virag R et al. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8 year experience with 615 cases. J Urol 1991; 145: 287-292.
26. Virag R, Frydman D, Legman M, Virag H. Intracavernous injection of papaverine as a diagnostic and therapeutic method in erectile failure. Angiology 1984; 35: 79.
27. Lue TF, Goldstein I. Introduction. In: Goldstein I and Lue TF eds. The Role of Alprostadil in the Diagnosis and Treatment of Erectile Dysfunction. 1993, Excerpta Medica, Inc: Princeton, 1-2.
28. Sharlip ID. Does natural erectile function improve following intracavernous injections of vasoactive drugs? Int J Impot Res; 1997; 9: 193-196.